Free Trial

Bristol Myers: 5yr Low

HEALTHCARE

Bristol Myers (BMY: A2 neg / A): Equity hits 5yr low


Bristol Myers hit a 5yr low stock price last night.

BMY has been highly acquisitive this year to replace a patent cliff which will see 60% of its sales under threat.

  • Karuna $14b, Mirati $4.8b, Rayzebio $4.1b were funded in the $ markets with a $14b multi-tranche deal in February.

The company has been on Neg Outlook with Moody’s since Feb and cut by S&P in Dec 23.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.